News und Analysen

Nvidia (NASDAQ: NVDA) shares declined 2.5% to close at $167.03 on July 22 as investors engaged in profit-taking following the stock's post-earnings rally. Approximately 183 million shares of the

First Financial (NASDAQ:THFF), a regional bank serving the Midwest and Southeast, delivered fiscal 2025 second-quarter results on Tuesday, July 22, that topped analysts' consensus expectations

Eli Lilly (NYSE: LLY) and Viking Therapeutics (NASDAQ: VKTX) have garnered considerable attention over the past year due to their solid clinical progress. However, these drugmakers have also lagged

A stock market that keeps reaching all-time highs hardly seems like anything for investors to complain about. But if you're trying to build a growing stream of passive income, extended bull markets

The trade war between the U.S. and China recently took an unexpected turn, and the biggest beneficiaries look to be Nvidia (NASDAQ: NVDA) and Advanced Micro Devices (NASDAQ: AMD). Both stocks popped

It's been an awful, horrible, lousy year so far for UnitedHealth Group (NYSE: UNH). If I opened a thesaurus, I could easily find plenty of other apt descriptions for the healthcare giant's

Few things can jolt a pharmaceutical company's shares like positive results from highly anticipated clinical trials. Even so, long-term investors should have a balanced approach to potentially

AT&T (NYSE: T) stock moved higher in Monday's trading. The telecommunications company's share price gained 1.6% in the daily session amid a 0.1% gain for the S&P 500 index and a 0.3% gain for the

In today's video, I discuss recent updates affecting Intel (NASDAQ: INTC) and Advanced Micro Devices (NASDAQ: AMD). To learn more, check out the short video, consider subscribing, and click the

In today's video, I discuss recent updates affecting Nvidia (NASDAQ: NVDA), Advanced Micro Devices (NASDAQ: AMD), and other semiconductor companies. To learn more, check out the short video,

Three years ago, Summit Therapeutics (NASDAQ: SMMT) was a little-known small-cap biotech that few investors with an average tolerance for risk would have bothered to pay attention to at the time

Pharmaceutical giants Pfizer (NYSE: PFE) and Novo Nordisk (NYSE: NVO) have lagged the market over the past year, although Pfizer's poor performance dates back much further. Though these companies

There is a lot you can do with $1,000. But if you want to get a step closer to sustainable wealth, consider putting that money to work in the stock market. The burgeoning generative artificial

Where can you find the next monster stocks? Check out the biotech space. It's not easy, but investors can sometimes find highly promising biotech stocks that are only in their early innings.

Three

President Donald Trump's trade policies have caused tumult on Wall Street. The president has pushed for aggressive tariffs on imported goods in an attempt to bring manufacturing jobs back to the

Merck (NYSE: MRK), a leading pharmaceutical company, generates consistent revenue and profits. However, the stock has been under pressure over the past year due to its reliance on Keytruda, its

One of the big reasons to like Pfizer (NYSE: PFE) today is its huge 7.1% dividend yield. To put that yield into context, the S&P 500 index is yielding roughly 1.3% and the average healthcare stock a

Medical device specialist DexCom (NASDAQ: DXCM) has encountered significant headwinds in the past year. The company's financial results haven't been quite up to the market's standards, and broader

David Tepper is one of the most successful investment managers on Wall Street. His Appaloosa Management hedge fund has produced gross annualized returns of more than 28% since its inception in 1993

A decade ago, shares of Exelixis (NASDAQ: EXEL), a biotech company specializing in oncology, were trading for under $10 per share. Today, the drugmaker's shares are changing hands for about $45

Investors seeking stocks that can put up dramatic gains in a short amount of time can find what they're looking for in the biotechnology industry. Investment bank analysts on Wall Street have tagged

Any investor who owned Viking Therapeutics (NASDAQ: VKTX) before November of last year is sure to be disappointed and maybe even a little worried. Shares are down nearly 60% since October last year